| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,380 | 21,620 | 13:04 | |
| 21,450 | 21,550 | 04.09. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 24,660 | 350 | |||
| 23,450 | 140 | |||
| 23,000 | 688 | |||
| 21,680 | 463 | |||
| 21,650 | 60 | |||
| 21,630 | 60 | |||
| 21,610 | 888 | |||
| 21,590 | 932 | |||
| 21,580 | 2.115 | |||
| 21,570 | 985 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gs71.htm [/URL] | ||||
| 1.164 | 21,480 | |||
| 1.138 | 21,460 | |||
| 1.853 | 21,450 | |||
| 1.039 | 21,440 | |||
| 60 | 21,430 | |||
| 60 | 21,410 | |||
| 463 | 21,300 | |||
| 200 | 19,300 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 5.977 | 1,118 | 6.681 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 04.09.2026 | 17:35:49 | 21,500 | 543 |
| 04.09.2026 | 17:29:18 | 21,480 | 86 |
| 04.09.2026 | 17:29:13 | 21,500 | 1 |
| 04.09.2026 | 17:17:32 | 21,505 | 75 |
| 04.09.2026 | 16:57:51 | 21,450 | 20 |
| 04.09.2026 | 16:51:35 | 21,440 | 2 |
| 04.09.2026 | 16:48:01 | 21,450 | 53 |
| 04.09.2026 | 16:43:28 | 21,470 | 156 |
| 04.09.2026 | 16:33:53 | 21,500 | 424 |
| 04.09.2026 | 16:33:53 | 21,490 | 74 |
| 04.09.2026 | 16:33:53 | 21,490 | 399 |
| 04.09.2026 | 16:30:57 | 21,490 | 15 |
| 04.09.2026 | 16:25:36 | 21,480 | 25 |
| 04.09.2026 | 16:16:24 | 21,440 | 58 |
| 04.09.2026 | 16:12:58 | 21,460 | 56 |
| 04.09.2026 | 16:08:55 | 21,480 | 84 |
| 04.09.2026 | 16:08:40 | 21,490 | 753 |
| 04.09.2026 | 16:08:03 | 21,480 | 20 |
| 04.09.2026 | 15:40:01 | 21,450 | 14 |
| 04.09.2026 | 15:11:57 | 21,450 | 21 |
| Tagesumsatz Xetra | -0,260 -1,19 % | 16.839 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GSK Aktie jetzt für 0€ handeln | |||||
| 04:26 | Can GSK's Hepatitis B Breakthrough Become a £2 Billion Opportunity? | 4 | Insider Monkey | ||
| Fr | Hutchmed, GSK Ink $1.3B Cancer Drug Deal | 9 | Contract Pharma | ||
| Do | GSK wagers up to $1.3B on a different kind of cancer drug | 11 | BioPharma Dive | ||
| Do | Hutchmed rises on $1.3bn KRAS licensing deal with GSK | 1 | pharmaphorum | ||
| Do | GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset | 3 | FierceBiotech |